PIK3CD and cancer: Although several unresolved complexities remain, catalytic subunit isoform-specific inhibition of the class I PI3K signaling pathway has become a therapeutic option in the treatment of cancer, inflammatory conditions, and immunodeficiencies associated with PI3K hyperactivation (8, 26, 38–42).